Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Jacobio to Start US/China Trials of KRAS Inhibitor in Solid Tumor Cancers

publication date: May 3, 2021

Beijing's Jacobio Pharma announced US approval to start trials of its KRAS G12C inhibitor in patients with advanced solid tumors. The company plans to enroll patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors that have the KRAS G12C mutation. So far, no KRAS G12C inhibitors have been approved globally. China approved a similar IND application in March. Jacobio will start enrolling patients for both trials in the second half of 2021. More details....

Stock Symbol: (HK: 1167)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021